Patents by Inventor Yuhong Zeng

Yuhong Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Viscosity-reducing compounds for protein formulations
    Patent number: 11696951
    Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: July 11, 2023
    Assignee: Comera Life Sciences, Inc.
    Inventors: Philip Wuthrich, Robert P. Mahoney, Subhashchandra Naik, Timothy Tran, Yuhong Zeng
  • EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
    Publication number: 20230027396
    Abstract: Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.
    Type: Application
    Filed: May 26, 2022
    Publication date: January 26, 2023
    Inventors: David S. Soane, Philip Wuthrich, Robert P. Mahoney, Yuhong Zeng, Subhashchandra Naik, Timothy Tran
  • STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
    Publication number: 20200270336
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Huixiang Zhang, Charles Boring, Alok Kulshreshtha, Yuhong Zeng, Li Wan, Laman Alani
  • Stable protein solution formulation containing high concentration of an anti-VEGF antibody
    Patent number: 10689438
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: June 23, 2020
    Assignee: Novartis AG
    Inventors: Huixiang Zhang, Charles Boring, Alok Kulshreshtha, Yuhong Zeng, Li Wan, Laman Alani
  • STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
    Publication number: 20160340420
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 24, 2016
    Inventors: Huixiang Zhang, Charles Boring, Alok Kulshreshtha, Yuhong Zeng, Li Wan, Laman Alani